2023-508767-79-00招募中1 期
A study to test how well different doses of BI 3034701 are tolerated by healthy men and people with overweight or obesity
Boehringer Ingelheim International GmbH, Boehringer Ingelheim International GmbH1 个研究点 分布在 1 个国家目标入组 125 人开始时间: 2024年4月22日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 125
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
CT Disclosure & Data Transparency
Scientific
Boehringer Ingelheim International GmbH
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A study to test how different doses of BI 1703880 in combination with ezabenlimab are tolerated in people with different types of advanced cancer (solid tumours)2024-511501-37-00Boehringer Ingelheim International GmbH18
招募中
1 期
A study to test how well different doses of BI 3804379 are tolerated by healthy people2024-513549-36-01Boehringer Ingelheim International GmbH106
招募中
1 期
A study to test different doses of BI 1831169 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors).2024-512504-19-00Boehringer Ingelheim International GmbH97
终止
2 期
Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).AsthmaNCT01396278Boehringer Ingelheim9
撤回
2 期
Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled CorticosteroidsAsthmaNCT01458912Boehringer Ingelheim